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Background: Same day discharge after elective PCI is rare in the Unites States, partly
due to concerns over access site complications associated with transfemoral intervention
(TFI). The timing of access site bleeding after TFI in the modern era of PCI is unclear.
Methods: 1525 consecutive patients undergoing elective PCI between January 2008 to May
2012 at a community hospital, were prospectively followed throughout their hospitalization.
Patients undergoing radial procedures, on warfarin, and those receiving intra-aortic balloon
pump were excluded. Early access site bleed was defined as any bleeding that occurred
within 6 hours of completion of procedure, and late bleeds were defined as those occurring
after 6 hours. Demographic , procedural and laboratory parameters were compared between
patients who had bleeding versus those who did not (Table 1).
Results: 78 patients (5.1%) developed access site bleeding. 70 events (90%) occurred less
than 6 hours after the procedure and 8 events (10%), after 6 hours. Median time to
bleeding was 30 minutes in the early group, and 7.75 hours in the late group, and 1
hour for the entire cohort. Results of univariate analysis are shown in Table 1, with female
gender and glycoprotein 2b/3a inhibitors identified as significant predictors of access site
bleeding. Multivariate analysis did not identify any predictors of late bleeds.
Conclusions: Majority of the access site bleeding events after transfemoral PCI occur within
six hours after the index procedure. Although these findings have favorable implications on
same day discharge strategy, a larger study to identify predictors of late bleeds is needed.
Access site bleed (N) No access site bleed (N) P-value
Female Gender 49/78 (62.8%) 514/1447 (35.5%) 0.001
Diabetes 27/78 (34.6%) 536/1447 (37.04%) 0.38
Hypertension 63/78 (80.76%) 1133/1447 (78.29%) 0.36
CABG 10/78 (12.82%) 228/1447 (15.75%) 0.30
GP2b3a 14/78 (17.94%) 157/144 (10.9%) 0.046
Bivalirudin 40/78 (51.28%) 861/1447 (59.5%) 0.47
Age 67.8  11.9 66.2  12.4 0.265
Height (Inches) 67.2  4.3 67.1  4.3 0.929
Weight (lbs) 192.1  42.4 193.2  46.8 0.826
Baseline Hemoglobin 13.3  1.9 13.3  1.9 0.691
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Background: Stroke after left cardiac catheterization is infrequent but it represents the
most debilitating complication from the patient perspective. Whereas the overall rate of
adverse events declined over the last decades, the incidence of periprocedural stroke has
remained unchanged. Ischemic stroke represents a high majority of symptomatic strokes
and the potential mechanisms underlying these events include thrombus or air emboliza-
tion, iatrogenic arterial dissection, hypotension and embolization debris of atheroma from
the aortic wall. Given the devastating consequence, we sought to identify incidence,
in-hospital outcomes and all modifiable and no modifiable risks factors of this adverse
event in a high volume center.
Methods: Our retrospective study included all patients experiencing periprocedural
ischemic stroke among 24500 patients who underwent left cardiac catheterization
between January 2003 and October 2010. The stroke group were compared with a case
group control of 500 individuals randomized from the initial source population.
Results: Ischemic cardiovascular events occurred in 46 patients (0.19% of procedures)
and included transient ischemic attack (TIA) in 16 cases and stroke in 30 cases. Hospital
stay was significantly prolonged (12.4 vs 8.2 days p0.001) and the in-hospital mortality
was higher (8.7% vs 0.6% p0.001) in stroke group. On multivariate analysis, diabetes
mellitus (adjusted odds ratio ¬(OR) 3,6; 95% confidence interval (CI) 1,7 to 7,7;
p0,001); chronic renal dysfunction (OR 2,4, 95% CI 1,1-5,4; p0,001), known
cerebrovascular disease (OR 7,3, 95% CI 3-17,8; p0,001) and recent congestive heart
failure (OR 2,6, 95% CI 1,1-6; p0,001) were independent predictors for stroke. The
independent modifiable predictive factors were represented by left ventricular angiogra-
phy (OR 5,6, 95% CI 2,2-13,8; p0,001), emergent cardiac catheterization (OR 4,5, 95%
CI 1,8-11,2; p0,01) and low operator volume (OR 2,7, 95% CI 1,3-3,8; p0, 01).
Conclusions: A really careful procedural planning taking account patients, procedural
risk factors and operator experience might still actually decrease the incidence of this
devastating complication.
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Background: The long-term clinical outcome of bulky covered stents in the percutaneous
treatment of diseased saphenous vein graft (SVG) has been disappointing. However, the single
self-expanding polytetrafluoroethylene (PTFE)-covered Symbiot stent with a unique profile,
has not been evaluated and may present advantages that translate into superior long-term
clinical outcomes. This study evaluated the safety, effectiveness and clinical outcome of the
SymbiotTM covered stent system (Boston Scientific, Natick, Mass.) and FilterWireTM EX
(Boston Scientific, Natick, Mass.) versus bare metal stents (BMS) in SVG intervention.
Methods: Between January 2003 and August 2005, 90 patients with degenerative SVG
lesions were prospectively randomized at 6 study sites to Symbiot implantation (n30),
BMS with FilterWire as embolic protection device (EPD, n30), or BMS without EPD
(control group, n30). The primary endpoint was reduction in peri-procedural cardiac
enzyme rise. The major secondary endpoints were in-hospital, 6 month and long-term
target vessel failure (TVF) rates, defined as the cumulative of death, myocardial infarction
and clinically-driven target lesion revascularization.
Results: There was no significant reduction in median [IQR] post-procedural troponin-I
rise in the Symbiot group compared to the FilterWire or the Control group (0.08 [0-1.40]
g/l; 0.06 [0-0.28] g/l; and 0.04 [0-0.31] g/l, p0.58). At 7.4  1.3 (mean  SD)
years of follow-up (Table), there were numerically less deaths in the Symbiot group,
although this did not reach statistical significance (p0.20). There was no significant
difference in TVF-free survival between the treatment groups (p0.98).
Clinical Events at Longest Available Clinical Follow-Up
Values are mean SD and event rates are Kalpan-Meier estimates (number
of events (%))
Symbiot
Group
FilterWire
group
Control
Group
p Value(n  30) (n  30) (n  30)
Long-Term Follow-Up
(years)
7.3  1.6 7.6  0.9 7.4  1.6 0.68
Death, all cause
In-hospital 1 (3) 1 (3) - 0.60
6 Months 3 (10) 2 (7) 1 (3) 0.58
Long -Term 6 (20) 13 (43) 11 (37) 0.20
Myocardial infarction
In-hospital 2 (7) 1 (3) 1 (3) 0.76
6 Months 2 (7) 2 (7) 2 (7) 1.00
Long -Term 7 (23) 5 (17) 7 (23) 0.69
Target lesion
revascularization
In-hospital 1 (3) - - 0.37
6 Months 3 (10) 2 (7) 1 (3) 0.59
Long -Term 8 (27) 5 (17) 10 (33) 0.32
Target vessel failure
In-hospital 3 (10) 1 (3) 1 (3) 0.42
6 Months 6 (20) 4 (13) 3 (10) 0.33
Long -Term 17 (57) 17 (57) 18 (60) 0.98
Values are mean  SD and event rates are Kaplan-Meier estimates (number of events (%))
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